<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04722354</url>
  </required_header>
  <id_info>
    <org_study_id>1545505</org_study_id>
    <nct_id>NCT04722354</nct_id>
  </id_info>
  <brief_title>Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity</brief_title>
  <acronym>ABA</acronym>
  <official_title>Abscisic Acid Effects on Glucose Homeostasis and Insulin Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotherapeutics, Inc (Study Sponsor); NIH (Funder)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of oral abscisic acid (ABA) on glucose&#xD;
      metabolism in subjects with defined prediabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 8, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>a randomized, cross-over, placebo-controlled trial will be employed to evaluate the effects of ABA (95ug) twice a day (190ug total per day) for 14 days on tolerability and insulin sensitivity during a hyperinsulinemic euglycemic clamp.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Monitoring adverse events</measure>
    <time_frame>10 weeks</time_frame>
    <description>Adverse events will be monitored at each visit throughout the duration of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>4-6 hours</time_frame>
    <description>Insulin sensitivity will be measured using hyperinsulinic euglycemic clamp</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Pre Diabetes</condition>
  <arm_group>
    <arm_group_label>ABA group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>95 ug 2x/day for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Corn Starch 300 mg for 14 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulemic euglycemic clamp</intervention_name>
    <description>Following a 12-hour overnight fast at the CRU (including abstinence from caffeine containing foods and beverages), insulin sensitivity will be measured using the criterion method of the euglycemic clamp. Participants will have not performed vigorous physical activity for at least the previous 24 h, and be free of acute illness for the prior 2 weeks. An intravenous catheter will be placed in an antecubital vein for subsequent insulin (40 mU/m2-min) and glucose infusions and for stable isotope (6, 6-2H2) infusions to measure insulin sensitivity.</description>
    <arm_group_label>ABA group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Muscle Biopsy</intervention_name>
    <description>One biopsy taken prior to clamp and a second biopsy taken 30-45 min after the start of the clamp. A biopsy of the Vastus Lateralis muscle will be performed on the leg/thigh using the Bergstrom technique.</description>
    <arm_group_label>ABA group</arm_group_label>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Oral abscisic acid (ABA)</intervention_name>
    <description>Those in this group will receive ABA (95 µg ABA and 300 mg of corn starch)</description>
    <arm_group_label>ABA group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Those in this group will receive placebo (300 mg cornstarch)</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Provision of signed and dated informed consent form&#xD;
&#xD;
          2. Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
          3. Male or female, aged 18-65&#xD;
&#xD;
          4. In good general health as evidenced by medical history or diagnosed with &lt;specify&#xD;
             condition/disease&gt; or exhibiting &lt;specify clinical signs or symptoms or physical/oral&#xD;
             examination findings&gt;&#xD;
&#xD;
          5. Fasting glucose &gt;5.6 and&lt;7.0 mmol/L and/or HbA1C &gt;5.6 and &lt;6.5 %&#xD;
&#xD;
          6. Ability to take oral medication and be willing to adhere to the &lt;study intervention&gt;&#xD;
             regimen&#xD;
&#xD;
          7. Females currently on hormone replacement therapy (HRT) can participate in the study if&#xD;
             they have been on HRT for at least 6 months and will continue to be on HRT during the&#xD;
             study.&#xD;
&#xD;
          8. For males of reproductive potential: use of condoms or other methods to ensure&#xD;
             effective contraception with partner&#xD;
&#xD;
          9. Agreement to adhere to Lifestyle Considerations throughout study duration.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Treated or untreated diabetes&#xD;
&#xD;
          2. 19&gt;BMI&lt;40.0 kg/m2&#xD;
&#xD;
          3. Blood pressure (BP) ≤ 150mmHg systolic and ≤ 95 mmHg diastolic&#xD;
&#xD;
          4. Current use of medications or antioxidant vitamins or supplements that would impact&#xD;
             dependent variables, including glucose metabolism.&#xD;
&#xD;
          5. Past or current ischemic heart disease, stroke, respiratory disease, endocrine or&#xD;
             metabolic disease, neurological disease, hematological-oncological disease and free of&#xD;
             recent infection (prior 2 weeks)&#xD;
&#xD;
          6. Pregnancy or lactation&#xD;
&#xD;
          7. Treatment with another investigational drug or other intervention within 1 year.&#xD;
&#xD;
          8. Current smoker or tobacco use within the past year.&#xD;
&#xD;
          9. Disqualifying findings on physical examination include cardiac murmurs, diminished&#xD;
             pulses or the presence of bruits in the lower extremities, lower extremity&#xD;
             thrombophlebitis, evidence of peripheral neuropathy, paresis or edema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bret Goodpaster, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>fh.tri.recruitment@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>AdventHealth Translational Research Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
      <phone>407-303-7100</phone>
      <email>Fh.tri.recruitment@adventhealth.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metabolism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abscisic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

